Trials / Active Not Recruiting
Active Not RecruitingNCT06198413
LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
A Dose-Escalation Study of LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD)
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Innostellar Biotherapeutics Co.,Ltd · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to evaluate the safety and efficacy of LX102 gene therapy for nAMD.
Detailed description
This study will enroll subjects aged ≥ 50 years old to receive a single unilateral subretinal injection of LX102 to evaluate its safety and efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | LX102 subretinal injection | LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap |
Timeline
- Start date
- 2023-02-27
- Primary completion
- 2024-12-26
- Completion
- 2029-01-01
- First posted
- 2024-01-10
- Last updated
- 2025-07-01
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06198413. Inclusion in this directory is not an endorsement.